About Hapten Sciences
Hapten Sciences is a company based in Memphis (United States) founded in 2010 by Raymond J Hage.. Hapten Sciences has raised $6.47 million across 8 funding rounds from investors including MB Venture Partners. Hapten Sciences offers products and services including Novel Biopharmaceutical Products. Hapten Sciences operates in a competitive market with competitors including Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others.
- Headquarter Memphis, United States
- Founders Raymond J Hage
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Hapten Sciences, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6.47 M (USD)
in 8 rounds
-
Latest Funding Round
$885.98 K (USD), Seed
Oct 31, 2019
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Hapten Sciences
Hapten Sciences offers a comprehensive portfolio of products and services, including Novel Biopharmaceutical Products. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Early-stage products aimed at improving global health through research
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Hapten Sciences
Hapten Sciences has successfully raised a total of $6.47M across 8 strategic funding rounds. The most recent funding activity was a Seed round of $885.98 thousand completed in October 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Seed — $885,980
-
First Round
First Round
(02 Jan 2014)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2019 | Amount | Seed - Hapten Sciences | Valuation |
investors |
|
| Sep, 2018 | Amount | Seed - Hapten Sciences | Valuation |
investors |
|
| Feb, 2017 | Amount | Seed - Hapten Sciences | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Hapten Sciences
Hapten Sciences has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include MB Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Capital and strategic direction are provided to life science companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Hapten Sciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Hapten Sciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Hapten Sciences Comparisons
Competitors of Hapten Sciences
Hapten Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Enliven Therapeutics, Nuvalent, Nura Bio, Abbisko Therapeutics and NewAmsterdam Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of drugs for solid tumours and blood cancers
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cancer, including NSCLC inhibitors, are developed.
|
|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
Developing novel small molecule drugs for immunomodulatory pathways to treat cancer
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for cardio-metabolic diseases are developed using obicetrapib.
|
|
| domain | founded_year | HQ Location |
RNA-modifying drug candidates are developed for multiple disorders.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about Hapten Sciences
When was Hapten Sciences founded?
Hapten Sciences was founded in 2010 and raised its 1st funding round 4 years after it was founded.
Where is Hapten Sciences located?
Hapten Sciences is headquartered in Memphis, United States. It is registered at Memphis, Tennessee, United States.
Who is the current CEO of Hapten Sciences?
Raymond J Hage is the current CEO of Hapten Sciences. They have also founded this company.
Is Hapten Sciences a funded company?
Hapten Sciences is a funded company, having raised a total of $6.47M across 8 funding rounds to date. The company's 1st funding round was a Seed of $1.2M, raised on Jan 02, 2014.
What does Hapten Sciences do?
Hapten Sciences is a privately held biopharmaceutical company that develops novel, early-stage products with the initial focus on dermatology conditions. Its initial product PDC-APB (HPT-721) is a small molecule that acts like a vaccine to prevent the contact dermatitis caused by exposure to urushiol oil in poison ivy, poison oak and poison sumac plants. It is also planning for final formulation analysis, pivotal toxicology studies, cGMP manufacturing, filing the Investigational New Drug (IND) application and clinical trials as next steps for its product.
Who are the top competitors of Hapten Sciences?
Hapten Sciences's top competitors include Nuvalent, Enliven Therapeutics and Abbisko Therapeutics.
What products or services does Hapten Sciences offer?
Hapten Sciences offers Novel Biopharmaceutical Products.
Who are Hapten Sciences's investors?
Hapten Sciences has 1 investor. Key investors include MB Venture Partners.